This page in English

Elizabeth Arkema

Forskarassistent

Besöksadress : Eugeniahemmet, T2, Karolinska Universitetssjukhuset, Solna 171 76 Stockholm
Postadress : Institutionen för medicin, Solna (MedS), K2, Forskargrupp J Askling, Eugeniahemmet, T2, Karolinska Universitetssjukhuset, Solna 171 76 Stockholm
Leveransadress : Eugeniahemmet, T2, Karolinska Universitetssjukhuset, Solna 171 76 Stockholm

Om mig

I am an epidemiologist with a research focus on the causes and consequences of chronic inflammatory diseases. 

Utbildning

ScD    Harvard School of Public Health, 2013

ScM    Harvard School of Public Health, 2009

AB       Princeton University, 2004

Forskningsbeskrivning

Sarcoidosis

I am currently the principal investigator of a multi-register data linkage project on sarcoidosis. For more information on my work on sarcoidosis, please visit our website: Sarcoidosis Epidemiology Research Group

Systemic Lupus Erythematosus

My work includes investigations of risk factors for systemic lupus erythematosus, outcomes after pregnancy in lupus and comorbidities associated with lupus such as stroke. 

Rheumatoid Arthritis

I began my career examining risk factors for rheumatoid arthritis using data from the Nurses' Health Studies. Since then, I have investigated adverse events associated with biological treatment in rheumatoid arthritis such as infection. 

 

Pedagogiska meriter

Co-organizer of Systemic Reviews and Meta-analyses (nr. 2790), organizer and lecturer

Länkar

Publikationer

Brief Report: Sex Ratio of Offspring Born to Women With Systemic Lupus Erythematosus or Rheumatoid Arthritis
Arkema Ev, Askling J, Salmon Je, Simard Jf
Arthritis & rheumatology (Hoboken, N.J.) 2017;69(1):143-147

Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers
Hellgren K, Dreyer L, Arkema Ev, Glintborg B, Jacobsson Lt, Kristensen Le, et al
Annals of the rheumatic diseases 2017;76(1):105-111

Cervical neoplasia in systemic lupus erythematosus: a nationwide study
Wadström H, Arkema Ev, Sjöwall C, Askling J, Simard Jf
Rheumatology (Oxford, England) 2017;56(4):613-619

Early-onset Preeclampsia in Lupus Pregnancy
Simard Jf, Arkema Ev, Nguyen C, Svenungsson E, Wikström Ak, Palmsten K, et al
Paediatric and perinatal epidemiology 2017;31(1):29-36

Elevated BMI and antibodies to citrullinated proteins interact to increase rheumatoid arthritis risk and shorten time to diagnosis: A nested case-control study of women in the Nurses' Health Studies
Tedeschi Sk, Cui J, Arkema Ev, Robinson Wh, Sokolove J, Lingampalli N, et al
Seminars in arthritis and rheumatism 2017;46(6):692-698

Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study
Svensson J, Arkema Ev, Lundberg Ie, Holmqvist M
Rheumatology (Oxford, England) 2017;56(5):802-810

Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based casecontrol study
Svensson J, Holmqvist M, Lundberg Ie, Arkema Ev
Annals of the rheumatic diseases 2017;76(11):1803-1808

Medication use among pregnant women with systemic lupus erythematosus and general population comparators
Palmsten K, Simard Jf, Chambers Cd, Arkema Ev
Rheumatology (Oxford, England) 2017;56(4):561-569

Mortality and Functionality after Stroke in Patients with Systemic Lupus Erythematosus
Rossides M, Simard Jf, Svenungsson E, Von Euler M, Arkema Ev
The Journal of rheumatology 2017;():-

Stroke in systemic lupus erythematosus: a Swedish population-based cohort study
Arkema Ev, Svenungsson E, Von Euler M, Sjöwall C, Simard Jf
Annals of the rheumatic diseases 2017;76(9):1544-1549

Case definitions in Swedish register data to identify systemic lupus erythematosus
Arkema Ev, Jönsen A, Rönnblom L, Svenungsson E, Sjöwall C, Simard Jf
BMJ open 2016;6(1):e007769-

Endometriosis and systemic lupus erythematosus: a population-based case-control study
Harris Hr, Simard Jf, Arkema Ev
Lupus 2016;25(9):1045-9

Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials
Emamikia S, Arkema Ev, Györi N, Detert J, Chatzidionysiou K, Dougados M, et al
RMD open 2016;2(2):e000323-

Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden
Arkema Ev, Grunewald J, Kullberg S, Eklund A, Askling J
The European respiratory journal 2016;48(6):1690-1699

What to Expect When Expecting With Systemic Lupus Erythematosus (SLE): A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLE
Arkema Ev, Palmsten K, Sjöwall C, Svenungsson E, Salmon Je, Simard Jf
Arthritis care & research 2016;68(7):988-94

Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?
Arkema Ev, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J, et al
Annals of the rheumatic diseases 2015;74(6):1212-7

Cohort profile: systemic lupus erythematosus in Sweden: the Swedish Lupus Linkage (SLINK) cohort
Arkema Ev, Simard Jf
BMJ open 2015;5(8):e008259-

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
Neovius M, Arkema Ev, Olsson H, Eriksson Jk, Kristensen Le, Simard Jf, et al
Annals of the rheumatic diseases 2015;74(2):354-60

Monocyte chemotactic protein-1 elevation prior to the onset of rheumatoid arthritis among women
Arkema Ev, Lu B, Malspeis S, Karlson Ew, Costenbader Kh
Biomarkers in medicine 2015;9(8):723-9

Perinatal risk factors for future SLE: a population-based nested case-control study
Arkema Ev, Simard Jf
Lupus 2015;24(8):869-74

Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies
Holmqvist M, Simard Jf, Asplund K, Arkema Ev
RMD open 2015;1(1):e000168-

Being overweight or obese and risk of developing rheumatoid arthritis among women: a prospective cohort study
Lu B, Hiraki Lt, Sparks Ja, Malspeis S, Chen Cy, Awosogba Ja, et al
ANNALS OF THE RHEUMATIC DISEASES 2014;73(11):1914-22

Circulating 25-hydroxyvitamin D level and risk of developing rheumatoid arthritis
Hiraki Lt, Arkema Ev, Cui J, Malspeis S, Costenbader Kh, Karlson Ew
Rheumatology (Oxford, England) 2014;53(12):2243-8

No association between rheumatoid arthritis, amyotrophic lateral sclerosis, and tumour necrosis factor inhibitor treatment
Arkema Ev, Feltelius N, Olsson T, Askling J, Artis Study Group
Annals of the rheumatic diseases 2014;73(11):2061-2

The Swedish Rheumatology Quality Register: optimisation of rheumatic disease assessments using register-enriched data
Eriksson Jk, Askling J, Arkema Ev
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2014;32(5):S-147

Anti-citrullinated peptide autoantibodies, human leukocyte antigen shared epitope and risk of future rheumatoid arthritis: a nested case-control study
Arkema Ev, Goldstein Bl, Robinson W, Sokolove J, Wagner Ca, Malspeis S, et al
Arthritis research & therapy 2013;15(5):R159-

Exposure to ultraviolet-B and risk of developing rheumatoid arthritis among women in the Nurses' Health Study
Arkema Ev, Hart Je, Bertrand Ka, Laden F, Grodstein F, Rosner Ba, et al
ANNALS OF THE RHEUMATIC DISEASES 2013;72(4):506-11

Patients with ulcerative colitis miss more days of work than the general population, even following colectomy
Neovius M, Arkema Ev, Blomqvist P, Ekbom A, Smedby Ke
Gastroenterology 2013;144(3):536-43

Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study
Arkema Ev, Van Vollenhoven Rf, Askling J, Artis Study Group
Annals of the rheumatic diseases 2012;71(11):1865-7

Is there a sex bias in prescribing anti-tumour necrosis factor medications to patients with rheumatoid arthritis? A nation-wide cross-sectional study
Arkema Ev, Neovius M, Joelsson Jk, Simard Jf, Van Vollenhoven Rf
Annals of the rheumatic diseases 2012;71(7):1203-6

Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers
Strangfeld A, Hyrich K, Askling J, Arkema E, Davies R, Listing J, et al
RHEUMATOLOGY 2011;50(1):146-51

Ten years with biologics: to whom do data on effectiveness and safety apply?
Simard Jf, Arkema Ev, Sundström A, Geborek P, Saxne T, Baecklund E, et al
Rheumatology (Oxford, England) 2011;50(1):204-13

A Prospective Study of Periodontal Disease and Risk of Rheumatoid Arthritis
Arkema Ev, Karlson Ew, Costenbader Kh
JOURNAL OF RHEUMATOLOGY 2010;37(9):1800-4

Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission
Kuriya B, Arkema Ev, Bykerk Vp, Keystone Ec
ANNALS OF THE RHEUMATIC DISEASES 2010;69(7):1298-304

Visa alla publikationer

Karta